Tectonic Therapeutic Inc/$TECX
1D1W1MYTD1Y5YMAX
Capital at risk
About Tectonic Therapeutic Inc
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
- Ticker
- $TECX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 60
- Headquarters
- Watertown, United States
- Website
- tectonictx.com
TECX Metrics
BasicAdvanced
$581M
-
-$4.56
0.22
-
Price and volume
Market cap
$581M
Beta
0.22
52-week high
$39.53
52-week low
$14.39
Average daily volume
214K
Financial strength
Current ratio
22.287
Quick ratio
21.899
Long term debt to equity
0.013
Total debt to equity
0.02
Interest coverage (TTM)
-2,373.13%
Profitability
EBITDA (TTM)
-93.661
Effective tax rate (TTM)
-0.39%
Management effectiveness
Return on assets (TTM)
-22.29%
Return on equity (TTM)
-33.80%
Valuation
Price to book
2.55
Price to tangible book (TTM)
2.55
Price to free cash flow (TTM)
-7.71
Free cash flow yield (TTM)
-12.97%
Free cash flow per share (TTM)
-3.853
Growth
Earnings per share change (TTM)
13.29%
Bulls say / Bears say
Completed enrollment in the global APEX Phase 2 trial of TX45 in PH-HFpEF, a critical execution milestone paving the way for topline results expected in early Q1 2027. (Reuters)
TX2100 Phase 1a healthy volunteer trial for HHT has dosed all six single-dose cohorts, with topline safety and PK results anticipated by end Q3 2026, demonstrating rapid advancement of the second program. (Company Press Release)
As of December 31, 2025, Tectonic held $253.8 million in cash and equivalents, providing a runway into Q4 2028 to fund pipeline progression without near-term financing risk. (SEC)
Net loss widened to $25.24 million in Q1 2026 from $15.91 million a year earlier, reflecting rising R&D and administrative expenses that may pressure long-term profitability. (SEC)
Topline results for TX2100 are not expected until end Q3 2026, leaving the HHT program in an unproven early stage and exposed to binary safety and PK readout risks. (Company Press Release)
TX45 APEX Phase 2 enrollment is nearing completion with topline data only anticipated in late Q4 2026 or early Q1 2027, prolonging the timeline to proof-of-concept and heightening execution risk. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
Upcoming events
No upcoming events
Funds containing TECX
AllUSDGBPEUR
Fund name | Fund size | $TECX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.